<DOC>
	<DOCNO>NCT01314014</DOCNO>
	<brief_summary>The purpose study determine whether Amplimexon ( imexon injection ) effective treatment indolent aggressive lymphoma progress treatment standard therapy .</brief_summary>
	<brief_title>Imexon Relapsed Follicular Aggressive Lymphomas</brief_title>
	<detailed_description>A phase II exploratory trial imexon lymphoma justify : ( 1 ) observation clinical activity ( partial response drug observe phase I test subject refractory indolent lymphoma ) ; ( 2 ) find imexon prevents development human immunoblastic lymphoma SCID mouse ; ( 3 ) find lymphoma cell line kill readily achievable dos ; ( 4 ) translational study implicate importance redox state cancer cell . The dose schedule chosen ( 1000 mg/m2 daily X 5 day every 3 week ) base tolerability subject acceptance prior AmpliMed phase I study . The planned correlative study help identify potential biomarkers response imexon provide insight potential mechanism imexon action hypothesize result prior laboratory study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>1 . Diagnosis : Group 1 : Histologically confirm indolent NHL , include follicular ( grade ) , small lymphocytic lymphoma , marginal zone lymphoma lymphoplasmacytic lymphomaGroup 2 : histologically confirm diffuse large Bcell , mantle cell , Burkitt , Burkittlike , diffuse large Bcell transform indolent nonHodgkin 's lymphoma . 2 . Prior treatment : Group 1 : ( indolent histology ) : Patients must demonstrate relapsed refractory disease 1 prior treatment regimen . The maximum number prior regimen use treatment specify . Group 2 : ( aggressive histology ) : Patients must demonstrate relapsed refractory disease least 1 prior treatment regimen . In case de novo diffuse large Bcell lymphoma , prior treatment must include RCHOP RCHOPlike therapy , well second line autologous stem cell transplantation unless patient eligible . The maximum number prior regimen specify . 3 . At least one target lesion , measurable radiographic method accord 2007 Revised Response Criteria Malignant Lymphoma . 4 . ECOG Performance Status 02 . 5 . No clinical laboratory evidence central nervous system disease . 6 . Adult ( age 18 year old ) . 7 . Projected life expectancy &gt; 4 month . 8 . If female , neither pregnant ( negative pregnancy test require screening ) lactating . 9 . If childbearing potential , must able use agree use medically acceptable contraception duration study . For female subject neither postmenopausal surgically sterilize , include oral injectable hormonal method , barrier method intrauterine device , diaphragm spermicide , condom spermicide , abstinence . Male subject must also agree use acceptable method contraception duration study . 10 . No major infection serious uncontrolled concomitant disease . Fully recovered major surgery . 11 . No evidence concurrent active malignancy . 12 . At least 4 week since prior cancer chemotherapy ( 2 week corticosteroid ) , antibody therapy , radiotherapy . 13 . Prior radiotherapy less estimate 25 % bone marrow . In addition , target lesion ( ) must previously irradiate . 14 . Clinical laboratory value within follow limit : 1 . Hgb &gt; /=10.0 g/dL 2 . Absolute neutrophil count ANC &gt; /=1,500/mm3 3 . Platelets &gt; /=75,000/mm3 4 . Serum creatinine &lt; /=2.0 time upper limit normal 5 . Serum bilirubin &lt; /=2.0 time upper limit normal 6 . Serum AST ALT &lt; /=3 time upper limit normal 15 . G6PD level &gt; /= low limit normal 16 . Able willing render inform consent follow protocol requirement . 1 . Diagnosis lymphoma base fine needle aspirate . 2 . Curative therapy indicate possible . 3 . Absence measurable target lesion , target lesion previously irradiate . 4 . Symptoms , exam finding , laboratory finding suggest central nervous system disease involvement . 5 . Age &lt; 18 year 6 . Projected life expectancy &lt; 4 month . 7 . Pregnant lactating . 8 . Unable unwilling use medically acceptable contraception , childbearing potential . 9 . Evidence major infection serious uncontrolled concomitant illness . Not fully recover prior major surgery . 10 . Evidence active malignancy . 11 . Prior radiotherapy , antibody therapy , cancer chemotherapy within 4 week start treatment ( 2 week corticosteroid ) . Prior radiotherapy &gt; 25 % bone marrow . 12 . Clinical laboratory value outside permitted range . 13 . Respiratory insufficiency require oxygen therapy ; angina rest , myocardial infarction previous 3 month ; history life threaten ventricular arrhythmia ; uncompensated CHF NYHA Grade 3 4 cardiac disease . 14 . Unable unwilling give inform consent follow protocol requirement . 15 . Failure meet eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Non Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma , Low Grade</keyword>
	<keyword>Lymphoma , Intermediate Grade</keyword>
	<keyword>Lymphoma , High Grade</keyword>
	<keyword>Lymphoma , B Cell</keyword>
</DOC>